Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tafenoquine plus DHA-Piperaquine

Phase 3Small molecule

MMenzies School of Health Research

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vivax MalariaNot yet recruiting

Vivax MalariaPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q2 2028

Post-ApprovalNot yet recruiting

Study completion

NCT07060794

Clinical

Trials by Indication[1]

Unspecified1 trial

Tafenoquine and ACTs (TADORE- Plus)

Not yet recruiting·MMenzies School of Health Research·Phase 4·NCT07060794·507 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tafenoquine plus DHA-Piperaquine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tafenoquine plus DHA-Piperaquine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tafenoquine plus DHA-Piperaquine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Menzies School of Health Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMenzies School of Health Research

Related News